PIWIL2 and pancreatic neoplasm: Patients with pancreatic tumor origin that exhibited a high expression of PIWIL2 presented longer median progression-free survival (median = 29 months; 95% CI: 17–40 months) than patients with low PIWIL2 expression (median = 11 months; 95% CI: 7–14 months) (p = 0.029; Figure 3A-top).